Literature DB >> 30307561

Inhibiting Adenosine Receptor Signaling Promotes Accumulation of Effector CD4+ T Cells in the Lung Parenchyma During Severe Tuberculosis.

Eduardo P Amaral1, Érika Machado de Salles1, Caio Cesar Barbosa Bomfim1, Rafael Moysés Salgado1, Fabrício M Almeida2, Paula Carolina de Souza1, José Maria Alvarez1, Mario H Hirata3, Elena B Lasunskaia2, Maria Regina D'Império-Lima1.   

Abstract

BACKGROUND: Tuberculous pneumonia, necrotic granulomatous lesions, and bacterial dissemination characterize severe forms of mycobacterial infection.
METHODS: To evaluate the pulmonary CD4+ T-cell response during severe tuberculosis, C57BL/6 mice were infected with approximately 100 bacilli of 3 hypervirulent mycobacterial isolates (Mycobacterium tuberculosis strain Beijing 1471 and Mycobacterium bovis strains B2 and MP287/03) or the H37Rv M tuberculosis strain as reference for mycobacterial virulence. Because high expression of both CD39 and CD73 ectonucleotidases was detected on parenchymal CD4+ T cells, we investigated whether CD4+ T-cell suppression in the context of severe disease was due to the extracellular adenosine accumulation that resulted from tissue damage.
RESULTS: Lowest expression of CD69, which is an activation marker implicated in maintaining cells in tissues, was observed in lungs from mice displaying the most severe pulmonary pathology. Reduced interferon (IFN)γ-producing CD4+ T cells were also found in the lung of these mice. Intranasal administration of the adenosine receptor antagonist caffeine substantially enhanced the frequency and number of parenchymal CD4+ T cells as well as both CD69 expression and IFNγ production.
CONCLUSIONS: These results indicate that adenosine, which may be generated by extracellular adenosine triphosphate degradation, impairs the parenchymal CD4+ T-cell response and contributes to the development of severe tuberculosis.
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  CD4+ T activation; adenosine; caffeine; immune response; severe tuberculosis

Year:  2019        PMID: 30307561     DOI: 10.1093/infdis/jiy586

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

1.  Harmful Effects of Granulocytic Myeloid-Derived Suppressor Cells on Tuberculosis Caused by Hypervirulent Mycobacteria.

Authors:  Caio César Barbosa Bomfim; Eduardo Pinheiro Amaral; Igor Santiago-Carvalho; Gislane Almeida Santos; Érika Machado Salles; Araceli Aparecida Hastreiter; Rogério Silva do Nascimento; Fabrício M Almeida; Thatiana Lopes Biá Ventura Simão; Andreza Linhares Rezende; Mario Hiroyuki Hirata; Ricardo Ambrósio Fock; José Maria Álvarez; Elena B Lasunskaia; Maria Regina D'Império Lima
Journal:  J Infect Dis       Date:  2021-02-13       Impact factor: 5.226

Review 2.  The Interplay Between Systemic Inflammation, Oxidative Stress, and Tissue Remodeling in Tuberculosis.

Authors:  Eduardo P Amaral; Caian L Vinhaes; Deivide Oliveira-de-Souza; Betania Nogueira; Kevan M Akrami; Bruno B Andrade
Journal:  Antioxid Redox Signal       Date:  2020-06-19       Impact factor: 8.401

3.  Severe Clinical Outcomes of Tuberculosis in Kharkiv Region, Ukraine, Are Associated with Beijing Strains of Mycobacterium tuberculosis.

Authors:  Olha Konstantynovska; Mariia Rekrotchuk; Ivan Hrek; Anton Rohozhyn; Nataliia Rudova; Petro Poteiko; Anton Gerilovych; Eric Bortz; Oleksii Solodiankin
Journal:  Pathogens       Date:  2019-06-10

Review 4.  Emerging patterns of regulatory T cell function in tuberculosis.

Authors:  A Ahmed; A Vyakarnam
Journal:  Clin Exp Immunol       Date:  2020-09-06       Impact factor: 4.330

Review 5.  Purinergic modulation of the immune response to infections.

Authors:  Natalia Eberhardt; Gastón Bergero; Yanina L Mazzocco Mariotta; M Pilar Aoki
Journal:  Purinergic Signal       Date:  2022-01-08       Impact factor: 3.765

Review 6.  Adenosine signaling: Optimal target for gastric cancer immunotherapy.

Authors:  Junqing Wang; Linyong Du; Xiangjian Chen
Journal:  Front Immunol       Date:  2022-09-16       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.